Teva Pharmaceutical Industries (TEVA) Finished Goods (2010 - 2018)

Teva Pharmaceutical Industries (TEVA) has reported Finished Goods for 9 consecutive years, with $2.7 billion the latest figure, recorded in Q4 2018.

• For the quarter ending Q4 2018, Finished Goods fell 0.89% year-over-year to $2.7 billion; the trailing twelve-month figure through Dec 2018 stood at $2.7 billion (down 0.89% YoY), and the FY2018 full-year result was $2.7 billion, down 0.89% from the prior year.
• Finished Goods retreated to $2.7 billion in Q4 2018 per TEVA's latest filing, from $2.7 billion in the prior quarter.
• Across five years, Finished Goods topped out at $2.9 billion in Q2 2017 and bottomed at $2.0 billion in Q1 2016.
• Historically, Finished Goods has averaged $2.5 billion across 5 years, with a median of $2.6 billion in 2014.
• The sharpest annual moves came in 2015 and 2017: Finished Goods decreased 16.08% in 2015, then soared 43.01% in 2017.
• Over 5 years, Finished Goods stood at $2.3 billion in 2014, then slipped by 9.61% to $2.1 billion in 2015, then surged by 38.15% to $2.8 billion in 2016, then decreased by 5.05% to $2.7 billion in 2017, then slipped by 0.89% to $2.7 billion in 2018.
• According to Business Quant data, Finished Goods over the past three periods registered $2.7 billion, $2.7 billion, and $2.7 billion for Q4 2018, Q3 2018, and Q2 2018 respectively.